Commentary|Videos|July 26, 2025
Gefurulimab Positive Phase 3 Data Released, PoNS Device Eyes Stroke Indication, AD109 Performs in Phase 3 LunAIRo Trial
Author(s)NeurologyLive® Staff
Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]
Advertisement
WATCH TIME: 4 minutes
AstraZeneca has announced positive data from its phase 3 PREVAIL study (NCT05556096), with investigational gefurulimab, a complement C5 inhibitor administered once-weekly, meeting primary and all secondary end points in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). The company is planning to share more from the study at an upcoming meeting and discuss the findings with global regulatory authorities. PREVAIL, a global, double-blind, placebo-controlled, parallel study, included 260 patients with gMG across 20 countries who were randomly assigned to gefurulimab or placebo for 26 weeks, followed by an optional open-label study. According to the company, treatment with the investigational agent displayed statistically significant and clinically meaningful differences vs placebo on the primary end point of Myasthenia Gravis-Activities of Daily Living (MG-ADL), a common measure for gMG trials.
Apnimed has announced positive data from its pivotal phase 3 , 12-month LunAIRo trial (NCT05811247) testing investigational AD109, a combination of aroxybutynin and atomoxetine, as a potential treatment for obstructive sleep apnea (OSA). These findings, along with previously announced phase 3 data from the SynAIRgy trial (NCT05813275), are expected to support a new drug application submission to the FDA in early 2026. In LunAIRo, treatment with the AD109 led to significant reductions in Apnea-Hypopnea Index (AHI), the primary end point, relative to those on placebo. At the 26-week mark, patients on the therapy achieved a mean reduction in AHI of 46.8% compared with reductions of 6.8% for placebo, which was statistically significant (P <.001). Notably, these effects were maintained out to the end of the study, around week 51 (P <.001).
For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5